Myostatin and activin A muscle wasting immunotherapy research program
preclinicalresearch program · high · Thu Jan 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Prevent or mitigate muscle and bone wasting, including sarcopenia-related loss of muscle performance.
Active immunization strategy targeting myostatin and activin A to inhibit negative regulators of muscle growth, evaluated in growth hormone-deficient and aged mouse models.
2026 GeroScience publication reported preclinical results; State of Florida grant announced on January 18, 2024 to support muscle and bone wasting research.
In mice, immunization improved grip strength, altered skeletal muscle transcriptomics, supported muscle remodeling, increased energy expenditure, and changed lipid metabolism in aged gastrocnemius muscle.
UB-313 anti-CGRP migraine immunotherapy
phase 1drug program · high · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Prevent migraine by inducing endogenous antibodies against calcitonin gene-related peptide.
Anti-CGRP peptide-based immunotherapeutic candidate evaluated in a first-in-human Phase 1 study of four dose regimens in healthy adults; preclinical studies assessed antibody titers, specificity, and pharmacodynamic activity.
ClinicalTrials.gov record describes a Phase 1 first-in-human study; 2025 publication reported preclinical characterization of active immunotherapy targeting CGRP.
Preclinical studies induced CGRP-specific antibodies in rats and non-human primates, with binding and activity potencies similar to marketed anti-CGRP monoclonal antibodies and in vivo efficacy in a rat pharmacodynamic model.
UB-612 COVID-19 vaccine booster
phase 3drug program · high · Wed Jan 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Provide a cross-platform heterologous COVID-19 booster for adults previously primed with mRNA, adenovirus-vectored, or inactivated COVID-19 vaccines.
Multicenter, international, randomized, active-controlled Phase 3 trial comparing UB-612 heterologous booster against homologous licensed-platform boosters.
Phase 3 trial completed on September 12, 2023; 2025 publication reported safety and immunogenicity outcomes.
UB-612 met primary and secondary immunogenicity endpoints, showed non-inferior neutralizing antibody responses versus homologous boosters, demonstrated superiority versus ChAdOx1-S and BBIBP-CorV on neutralizing antibody GMT and seroresponse rates, and was well tolerated with similar safety profiles.
Alzheimer's and Parkinson's disease prevention research program
exploratoryresearch program · medium · Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Further develop active immunotherapies to prevent and mitigate neurodegenerative diseases including Alzheimer's and Parkinson's disease.
Research program funded by a State of Florida grant, supported by active immunotherapy publications and programs involving amyloid beta, alpha-synuclein, and tau.
State of Florida grant announced on January 30, 2024 to support neurodegenerative disease prevention and mitigation research.
A 2024 publication is listed on active immunotherapy for the prevention of Alzheimer's and Parkinson's disease.
UB-312 alpha-synuclein immunotherapy
phase 1drug program · high · Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Target pathological alpha-synuclein for Parkinson's disease and related neurodegenerative disease applications.
Active immunotherapeutic peptide vaccine evaluated in placebo-controlled Phase 1 studies for safety, tolerability, immunogenicity, pharmacodynamics, and target engagement.
2024 publication reported target engagement and immunogenicity of an active immunotherapeutic targeting pathological alpha-synuclein.
Published evidence reports target engagement and immunogenicity in a Phase 1 placebo-controlled trial.
VXX-401 anti-PCSK9 vaccine
phase 1drug program · high · Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Lower LDL-C for hypercholesterolemia by inducing antibodies against PCSK9.
Anti-PCSK9 peptide-based immunotherapeutic candidate evaluated in a first-in-human intramuscular clinical study for safety, tolerability, immunogenicity, pharmacodynamics, and dose regimen selection.
ClinicalTrials.gov record describes an active first-in-human study; 2024 publication reported LDL-C reduction in cynomolgus monkeys.
Preclinical publication title reports that VXX-401 reduced LDL-C in cynomolgus monkeys.
UB-311 Alzheimer's disease immunotherapy
phase 2drug program · high · Sun Jan 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat mild Alzheimer's disease by inducing antibodies against amyloid beta.
Randomized, double-blind, placebo-controlled Phase 2a study of active immunotherapy in participants with mild Alzheimer's disease.
2023 Lancet-linked publication reported Phase 2a safety, tolerability, immunogenicity, and efficacy data.
The supplied material identifies a Phase 2a study of UB-311 in mild Alzheimer's disease, but does not provide detailed numerical outcomes.
Active Immunotherapy Medicine platform
undisclosedplatform · high
Harness the immune system to induce endogenous antibody production against chronic disease targets.
Synthetic peptide active immunotherapy platform designed to mimic biological epitopes, break immune tolerance, and stimulate antibody production.
Company site describes the platform as the basis for programs across COVID-19, Parkinson's disease, Alzheimer's disease, PCSK9, tau, and other targets.
Anti-tau immunotherapy program
undiscloseddrug program · medium
Develop active immunotherapy against tau for neurodegenerative disease applications.
Active immunotherapy program referenced in the company pipeline list.
Listed in supplied site analysis as an anti-tau program.
